Main description:

This book is designed to fill a need for a comprehensive but compact and easy-to-use reference for all mental health professionals dealing with children and adolescents. The new edition of the widely praised handbook summarizes the latest information from the published literature (scientific data, controlled clinical trials, case reports) and clinical experience in compact and easy-to-use charts and bulleted lists for each class of psychotropic drug used in children and adolescents. The spiralbound handbook includes for each class of drugs both monograph statements on use in children and adolescents and approved indications, as well as the available data concerning off-label indications, findings from open and double-blind studies concerning doses, adverse affects, and other considerations in these age groups. For each class of drug, summary information is provided on: Classification; Product availability; Indications; Pharmacology; Dosing; Pharmacokinetics; Adverse effects; Withdrawal; Precautions; Toxicity; Nursing implications; Drug interactions; Contraindications; Patient instructions; and Interactions.

Contents:

Introduction; Psychiatric Disorders in Children and Adolescents; Attention Deficit Hyperactivity Disorder (ADHD); Major Depressive Disorder (MDD); Bipolar Disorder (BD); Schizophrenia; Anxiety Disorders; Tic Spectrum Disorders; Pervasive Developmental Disorders (PDD); Disruptive Behavior Disorders; Drugs for Attention Deficit Hyperactivity Disorder; Psychostimulants; Atomoxetine; Clonidine; Augmentation Strategies in ADHD; Antidepressants; Selective Serotonin Reuptake Inhibitors (SSRI); Norepinephrine Dopamine Reuptake Inhibitor (NDRI); Selective Serotonin Norepinephrine Reuptake Inhibitor (SNRI); Serotonin-2 Antagonists/Reuptake Inhibitors (SARI); Noradrenergic/Specific Serotonergic Antidepressants (NaSSA); Nonselective Cyclic Antidepressants; Monoamine Oxidase Inhibitors; Reversible Inhibitor of MAO-A (RIMA); Irreversible Monoamine Oxidase Inhibitors; Antidepressant Doses; Effects of Antidepressants on Neurotransmitters/Receptors; Pharmacological Effects of Antidepressants on Neurotransmitters/Receptors; Adverse Reactions to Cyclic Antidepressants at Therapeutic Doses; Switching Antidepressants; Antidepressant Augmentation Strategies; Electroconvulsive Treatment; Antipsychotics (Neuroleptics); Second-Generation Antipsychotics (Neuroleptics); Third-Generation Antipsychotics (Neuroleptics); First-Generation Antipsychotics (Neuroleptics); Antipsychotic Doses; Effects of Antipsychotics on Neurotransmitters/Receptors; Pharmacological Effects of Antipsychotics on Neurotransmitters/Receptors; Adverse Reactions to Antipsychotics at Therapeutic Doses; Comparison of Depot Antipsychotics; Extrapyramidal Side Effects of Antipsychotics; Switching Antipsychotics; Antipsychotic Augmentation Strategies; Agents for Treating Extrapyramidal Side Effects; Comparison of Agents for Treating Extrapyramida Side Effects; Anxioloytic Agents; Benzodiazepines; Comparison of the Benzodiazepines; Buspirone; Hypnotics/Sedatives; Comparison of Hypnotics/Sedatives; Mood Stabilizers; Lithium; Anticonvulsants; Comparison of Anticonvulsants; Adverse Reactions to Mood Stabilizers at Therapeutic Doses; Drugs of Abuse; Stimulants; Hallucinogens; Alcohol; Opiates/Narcotics; Inhalants/Aerosols; Gamma Hydroxy Butyrate (GHB); Flunitrazepam (Rohypnol); Treatment of Substance Use Disorders; Disulfiram; Methadone; Other Treatments of Psychiatric Disorders; Adrenergic Agents; Cholinergic Agents; Dopaminergic Agents; GABA Agents/Anticonvulsants; Miscellaneous; Herbal and "Natural" Products; Patient and Caregiver Information Sheets; Glossary; Index of Drugs.